Pharmaceutical manufacturer Laurus Labs said that its has entered into a strategic partnership agreement with United Nations’ The Global Fund to sell a generic version of Viiv Healthcare’s dolutegravir (DTG) tablets in the Sub-Saharan countries for three years.
Tenofovir/Lamivudine/Dolutegravir (TLD) is a combination drug used for the treatment of HIV/AIDS.
Laurus had previously received approval from the US Food and Drug Administration to launch the drug in February 2019.
The drugs will be sold in doses of 50 mg and 300 mg.
Established in 2007, Laurus Labs sells its products in more than 56 countries. The company’s focus areas include drugs for the treatment of cancer and Hepatitis C.
The Global Fund (The Global Fund to Fight AIDS, Tuberculosis and Malaria) is an international financing organisation established by the United Nations.
The organisation commenced its operations in January 2002. The Global Fund is the world’s largest financier of AIDS, TB, malaria prevention, treatment and care programs.